Xuan Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xuan Dong has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Fanyu Bu
5 shared publicationsLongqi Liu
5 shared publications- Ying Gu
BGI research, Shenzhen, China
5 shared publications Haibo Zhang
4 shared publicationsHaitao Xiang
4 shared publications- Longqi Liu
College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
4 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7549
Uncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq
- 3 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7549
Open AccessUncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq
- 28 February 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 106
Mesenchymal stem cells-derived exosome relieves imiquimod-induced psoriasis‐like dermatitis by targeting keratinocyte differentiation
- 28 February 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 106
Mesenchymal stem cells-derived exosome relieves imiquimod-induced psoriasis‐like dermatitis by targeting keratinocyte differentiation
- Open Access
- 22 January 2026
- Published by Elsevier in Cell Genomics
- Vol. 6 (2) , 101163
Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC
- 22 January 2026
- Published by Elsevier in Cell Genomics
- Vol. 6 (2) , 101163
Open AccessPredominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC
- Open Access
- 21 January 2026
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 15
Integrative single-cell transcriptomics and proteomics reveal an immunometabolic framework for MSC-exosome-mediated remodeling of expanded NK cells
Natural killer (NK) cells play a central role in anti-tumor immunity and immunosurveillance of senescence, yet their clinical performance is frequently limited by functional exhaustion during ex vivo expansion. Mesenchymal stem cell-derived exosomes (MSC-Exos) are increasingly recognized as immunomodulators, but their broader effects on NK cell fitness and functional states remain incompletely characterized. Here, we assessed MSC-Exos-mediated regulation of human NK cells using a standardized ex vivo priming platform integrated with single-cell transcriptomics and proteomic profiling. MSC-Exos significantly improved NK cell viability in a dose- and time-dependent manner while preserving a CD56⁺CD3⁻ NK-cell-enriched phenotype. MSC-Exos-treated NK cells showed enhanced cytotoxicity against K562 tumor cells and senescent fibroblasts. This phenotype was accompanied by increased expression of the activating receptors NKG2D and CD16, reduced LAG3 expression, and enhanced granzyme B expression and degranulation. Consistent with improved NK cell fitness, MSC-Exos treatment was also associated with upregulated expression of genes involved in NRF2-linked redox programs and improved mitochondrial readouts in NK cells. Single-cell analyses of MSC-Exos-treated NK cells revealed enhanced immune-effector programs and reduced inflammatory stress, while trajectory inference indicated that MSC-Exos may bias the NK cell state distribution toward more cytotoxic effector-like states. Proteomic profiling of MSC-Exos identified enrichment of FcγR-associated signaling components, supporting the hypothesis that exosomal composition may be related to the FcγR/CD16-associated transcriptional and phenotypic features observed in MSC-Exos-treated NK cells. Our data indicate that MSC-Exos improve NK cell viability and functional fitness during ex vivo expansion and bias NK cells toward a more effector-cytotoxic state. Together, these findings provide an immunometabolic framework for MSC-Exos-assisted NK cell manufacturing, while underscoring the need for further causal validation.
- 21 January 2026
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 15
Open AccessIntegrative single-cell transcriptomics and proteomics reveal an immunometabolic framework for MSC-exosome-mediated remodeling of expanded NK cells
Natural killer (NK) cells play a central role in anti-tumor immunity and immunosurveillance of senescence, yet their clinical performance is frequently limited by functional exhaustion during ex vivo expansion. Mesenchymal stem cell-derived exosomes (MSC-Exos) are increasingly recognized as immunomodulators, but their broader effects on NK cell fitness and functional states remain incompletely characterized. Here, we assessed MSC-Exos-mediated regulation of human NK cells using a standardized ex vivo priming platform integrated with single-cell transcriptomics and proteomic profiling. MSC-Exos significantly improved NK cell viability in a dose- and time-dependent manner while preserving a CD56⁺CD3⁻ NK-cell-enriched phenotype. MSC-Exos-treated NK cells showed enhanced cytotoxicity against K562 tumor cells and senescent fibroblasts. This phenotype was accompanied by increased expression of the activating receptors NKG2D and CD16, reduced LAG3 expression, and enhanced granzyme B expression and degranulation. Consistent with improved NK cell fitness, MSC-Exos treatment was also associated with upregulated expression of genes involved in NRF2-linked redox programs and improved mitochondrial readouts in NK cells. Single-cell analyses of MSC-Exos-treated NK cells revealed enhanced immune-effector programs and reduced inflammatory stress, while trajectory inference indicated that MSC-Exos may bias the NK cell state distribution toward more cytotoxic effector-like states. Proteomic profiling of MSC-Exos identified enrichment of FcγR-associated signaling components, supporting the hypothesis that exosomal composition may be related to the FcγR/CD16-associated transcriptional and phenotypic features observed in MSC-Exos-treated NK cells. Our data indicate that MSC-Exos improve NK cell viability and functional fitness during ex vivo expansion and bias NK cells toward a more effector-cytotoxic state. Together, these findings provide an immunometabolic framework for MSC-Exos-assisted NK cell manufacturing, while underscoring the need for further causal validation.
- Open Access
- 13 November 2025
- Published by Elsevier in Cell Genomics
- Vol. 6 (1) , 101062
Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC
- 13 November 2025
- Published by Elsevier in Cell Genomics
- Vol. 6 (1) , 101062
Open AccessPredominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC
- Open Access
- 14 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7534
Single-cell eQTL mapping of human endogenous retroviruses reveals cell type-specific genetic regulation in autoimmune diseases
Human endogenous retroviruses constitute a significant portion of the human genome and play complex roles in gene regulation and disease processes. However, the expression pattern and disease associations of specific retroviral loci remain pooly understood. This study examines the expression and regulatory mechanisms of these retroviral elements in immune cells. Utilizing single-cell RNA sequencing data from peripheral blood mononuclear cells, we identify 41,460 expressed retroviral loci, with 1936 showing cell type-specific expression. We further detect 3463 conditionally independent expression quantitative trait loci linked to retroviral elements, highlighting their potential role in mediating genetic variants and disease associations. Notably, these retroviral sequences associate significantly with autoimmune diseases, with specific loci demonstrating pleiotropic associations with disease-related genes. Our findings suggest that these elements are not merely genomic remnants but active participants in cellular regulation and disease progression. This work advances understanding of human-retroviral coevolution and highlights potential therapeutic targets in immune disorders.
- 14 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7534
Open AccessSingle-cell eQTL mapping of human endogenous retroviruses reveals cell type-specific genetic regulation in autoimmune diseases
Human endogenous retroviruses constitute a significant portion of the human genome and play complex roles in gene regulation and disease processes. However, the expression pattern and disease associations of specific retroviral loci remain pooly understood. This study examines the expression and regulatory mechanisms of these retroviral elements in immune cells. Utilizing single-cell RNA sequencing data from peripheral blood mononuclear cells, we identify 41,460 expressed retroviral loci, with 1936 showing cell type-specific expression. We further detect 3463 conditionally independent expression quantitative trait loci linked to retroviral elements, highlighting their potential role in mediating genetic variants and disease associations. Notably, these retroviral sequences associate significantly with autoimmune diseases, with specific loci demonstrating pleiotropic associations with disease-related genes. Our findings suggest that these elements are not merely genomic remnants but active participants in cellular regulation and disease progression. This work advances understanding of human-retroviral coevolution and highlights potential therapeutic targets in immune disorders.
- 10 January 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 298, 139740
PcoCas12a: A novel CRISPR enzyme from Prevotella copri enhancing TCR-T-cell tumor suppression
- 10 January 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 298, 139740
PcoCas12a: A novel CRISPR enzyme from Prevotella copri enhancing TCR-T-cell tumor suppression
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
SpatialSNV: A novel method for identifying and analyzing spatially resolved SNVs in tumor microenvironments
Background: The dynamics of single-nucleotide variants (SNVs) play a critical role in understanding tumor development, yet their influence on shaping tumor microenvironments remains largely unexplored. Spatial transcriptomics offers an opportunity to map SNVs within the tumor context, potentially uncovering new insights into tumor microenvironment dynamics. Results: This study developed SpatialSNV for identifying effective SNVs across tumor sections using multiple spatial transcriptomics platforms. The analysis revealed that SNVs reflect regional tumor evolutionary traces and extend beyond RNA expression changes. The tumor margins exhibited a distinct mutational profile, with novel SNVs diminishing in a distance-dependent manner from the tumor boundary. These mutations were significantly linked to inflammatory and hypoxic microenvironments. Furthermore, spatially correlated SNV groups were identified, exhibiting distinct spatial patterns and implicating specific roles in tumor–immune system crosstalk. Among these, critical SNVs such as S100A11L40P in colorectal cancer were identified as tumor region–specific mutations. This mutation, located within exonic nonsynonymous regions, may produce neoantigens presented by HLAs, marking it as a potential therapeutic target. Conclusions: SpatialSNV represents a promising framework for unraveling the mechanisms underlying tumor–immune crosstalk within the tumor microenvironment by leveraging spatial transcriptomics and SNV-based tissue domain characterization. This approach is designed to be scalable, integrative, and adaptable, making it accessible to researchers aiming to explore tumor heterogeneity and identify therapeutic targets.
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
Open AccessSpatialSNV: A novel method for identifying and analyzing spatially resolved SNVs in tumor microenvironments
Background: The dynamics of single-nucleotide variants (SNVs) play a critical role in understanding tumor development, yet their influence on shaping tumor microenvironments remains largely unexplored. Spatial transcriptomics offers an opportunity to map SNVs within the tumor context, potentially uncovering new insights into tumor microenvironment dynamics. Results: This study developed SpatialSNV for identifying effective SNVs across tumor sections using multiple spatial transcriptomics platforms. The analysis revealed that SNVs reflect regional tumor evolutionary traces and extend beyond RNA expression changes. The tumor margins exhibited a distinct mutational profile, with novel SNVs diminishing in a distance-dependent manner from the tumor boundary. These mutations were significantly linked to inflammatory and hypoxic microenvironments. Furthermore, spatially correlated SNV groups were identified, exhibiting distinct spatial patterns and implicating specific roles in tumor–immune system crosstalk. Among these, critical SNVs such as S100A11L40P in colorectal cancer were identified as tumor region–specific mutations. This mutation, located within exonic nonsynonymous regions, may produce neoantigens presented by HLAs, marking it as a potential therapeutic target. Conclusions: SpatialSNV represents a promising framework for unraveling the mechanisms underlying tumor–immune crosstalk within the tumor microenvironment by leveraging spatial transcriptomics and SNV-based tissue domain characterization. This approach is designed to be scalable, integrative, and adaptable, making it accessible to researchers aiming to explore tumor heterogeneity and identify therapeutic targets.
- Top Cited PapersOpen Access
- 26 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients
Colorectal cancer (CRC) patients with mismatch repair (MMR)-deficient (dMMR) but not MMR-proficient (pMMR) tend to benefit from immune checkpoint blockade (ICB) therapy. To profile the tumor microenvironments (TME) underlying these varied therapeutic responses, we integrate spatial enhanced resolution omics-sequencing (Stereo-seq), single-cell RNA sequencing, and multiplexed imaging analysis to create high-definition spatial maps of tumors from treatment-naïve and ICB-treated CRC patients. Our results identify the spatial organization and immune status of the tumor-stroma boundary as a distinctive feature of dMMR and pMMR CRCs, which associates with ICB response. The physical interactions and abundance of LAMP3+DCs and CXCL13+T cells may shape the ICB-responsive tumor-stroma boundary, whereas CXCL14+cancer-associated fibroblasts tend to remodel extracellular matrix to form a structural barrier in non-responders. Our work therefore points out the importance of the molecular and cellular spatial structures of tumors in ICB response, raising the possibility of reprogramming tumor-stroma boundary for sensitizing immunotherapies in the majority of CRCs.
- 26 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Top Cited PapersOpen AccessSpatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients
Colorectal cancer (CRC) patients with mismatch repair (MMR)-deficient (dMMR) but not MMR-proficient (pMMR) tend to benefit from immune checkpoint blockade (ICB) therapy. To profile the tumor microenvironments (TME) underlying these varied therapeutic responses, we integrate spatial enhanced resolution omics-sequencing (Stereo-seq), single-cell RNA sequencing, and multiplexed imaging analysis to create high-definition spatial maps of tumors from treatment-naïve and ICB-treated CRC patients. Our results identify the spatial organization and immune status of the tumor-stroma boundary as a distinctive feature of dMMR and pMMR CRCs, which associates with ICB response. The physical interactions and abundance of LAMP3+DCs and CXCL13+T cells may shape the ICB-responsive tumor-stroma boundary, whereas CXCL14+cancer-associated fibroblasts tend to remodel extracellular matrix to form a structural barrier in non-responders. Our work therefore points out the importance of the molecular and cellular spatial structures of tumors in ICB response, raising the possibility of reprogramming tumor-stroma boundary for sensitizing immunotherapies in the majority of CRCs.
- Open Access
Immunogenic peptides putatively from intratumor microbes: Opportunities for colorectal cancer treatment